Background: Serotonin (5-HT) may play an important role in the regulation of colonic motility in humans. However, it is not known whether alterations in the colonic 5-HT system are involved in the pathophysiology of irritable bowel syndrome (IBS). Methods: Colonic mucosal specimens ranging from the ascending colon to the rectum were obtained from patients with diarrhea- or constipation-predominant IBS (n = 7 and n = 8, respectively) and from subjects with normal bowel habits (n = 7) by endoscopic biopsy in order to determine whether patients with different clinical manifestations of IBS have different mucosal disposition of 5-HT. The tissue concentrations of 5-HT and its major metabolite, 5-hydroxyindoleacetic acid, were determined by reversed-phase high-performance liquid chromatography with fluorescence detection. Results: In all study groups, the mean mucosal 5-HT concentrations obtained from the rectum were significantly (p < 0.05) higher than those obtained from more cephalic regions of the colon. In addition, the overall mean mucosal 5-HT concentrations obtained from patients with constipation-predominant IBS were significantly (p < 0.05) higher than those obtained from the control subjects and patients with diarrhea-predominant IBS. No significant differences were observed in 5-hydroxyindoleacetic acid concentrations among the three groups. Conclusions: The mucosal 5-HT concentrations in the colon showed an ascending cephalocaudal gradient in all study groups. Although the mucosal 5-HT concentrations were elevated in patients with constipation-predominant IBS as compared with those with diarrhea-predominant IBS and the control subjects, further studies are necessary to determine whether the elevated mucosal 5-HT is a cause or a result of abnormal colonic motility.

Journal Section:
Original Paper: Irritable Bowel Syndrome
Keywords:
Serotonin, Irritable bowel syndrome, Colonic dysmotility, Constipation, Diarrhea
1.
Foxx-Orenstein AE, Kuemmerle JF, Grider JR: Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine. Gastroenterology 1996;111:1281&ndash;1290.
[PubMed]
2.
Appel S, Kumle A, Meier R: Clinical pharmacodynamics of SDZ HTF919, a new 5-HT4 receptor agonist, in a model of slow colonic transit. Clin Pharmacol Ther 1997;62:546&ndash;555.
[PubMed]
3.
Zimmerman TW, Binder HJ: Serotonin-induced alteration of colonic electrolyte transport in the rat. Gastroenterology 1984;86:310&ndash;317.
[PubMed]
4.
Sidhu M, Cooke HJ: Role for 5-HT and ACh in submucosal reflexes mediating colonic secretion. Am J Physiol 1995;269:G346&ndash;G351.
[PubMed]
5.
von der Ohe MR, Camilleri M, Kvols LK, Thomforde GM: Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med 1993;329:1073&ndash;1078.
[PubMed]
https://doi.org/10.1056/NEJM199310073291503
6.
Grider JR, Kuemmerle JF, Jin JG: 5-HT released by mucosal stimuli initiates peristalsis by activating 5-HT4/5-HT1p receptors on sensory CGRP neurons. Am J Physiol 1996;270:G778&ndash;G782.
[PubMed]
7.
Steadman CJ, Talley NJ, Phillips SF, Zinsmeister AR: Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: A pilot study. Mayo Clin Proc 1992;67:732&ndash;738.
[PubMed]
8.
Prior A, Read NW: Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5-HT3 receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993;7:175&ndash;180.
[PubMed]
9.
Talley NJ, Phillips SF, Haddad A, Miller LJ, Twomey C, Zinsmeister AR: GR38032F (ondansetron), a selective 5-HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990;35:477&ndash;480.
[PubMed]
10.
Gore S, Gilmore IT, Haigh CG, Brownless SM, Stockdale H, Morris AI: Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 1990;4:139&ndash;144.
[PubMed]
11.
Erspamer V, Asero B: Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. Nature 1952;169:800&ndash;801.
12.
Lincoln J, Crowe R, Kamm MA, Burnstock G, Lennard-Jones JE: Serotonin and 5-hydroxyindoleacetic acid are increased in the sigmoidal colon in severe idiopathic constipation. Gastroenterology 1990;98:1219&ndash;1225.
[PubMed]
13.
Drossman DA, Thompson GW, Talley NJ, Funch-Jensen P, Janssens J, Whitehead WE: Identification of subgroups of functional gastrointestinal disorders. Gastroenterol Int 1990;3:159&ndash;172.
14.
Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248&ndash;254.
[PubMed]
https://doi.org/10.1006/abio.1976.9999
15.
Koyama E, Minegishi A, Ishizaki T: Simultaneous determination of four monoamine metabolites and serotonin in cerebrospinal fluid by &lsquo;high-perfomance&rsquo; liquid chromatography with electrochemical detection: Application for patients with Alzheimer&rsquo;s disease. Clin Chem 1988;34:680&ndash;684.
[PubMed]
16.
Kosterlitz HW, Lees GM: Pharmacological analysis of intrinsic intestinal reflexes. Pharmacol Rev 1964;16:301&ndash;339.
17.
Zhao R, Baig MK, Wexner SD, Chen W, Singh JJ, Nogueras JJ, Woodhouse S: Enterochromaffin and serotonin cells are abnormal for patients with colonic inertia. Dis Colon Rectum 2000;43:858&ndash;863.
[PubMed]
18.
El-Salhy M, Norrgard O, Spinnell S: Abnormal colonic endocrine cells in patients with chronic idiopathic slow-transit constipation. Scand J Gastroenterol 1999;34:1007&ndash;1011.
[PubMed]
https://doi.org/10.1080/003655299750025110
19.
Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD: Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 1996;16:2352&ndash;2364.
[PubMed]
20.
Sanders-Bush E, Mayer SE: 5-Hydroxytryptamine (serotonin) receptor agonists and antagonists; in Hardman JG, Limbird LE, Molinoff PB, Ruddon R (eds): Goodman &amp; Gilman&rsquo;s The Pharmacological Basis of Therapeutics, ed 9. New York, McGraw Hill, 1996, pp 249&ndash;263.
21.
Chugani DC, Muzik O, Chakraborty P, Mangner T, Chugani HT: Human brain serotonin synthesis capacity measured in vivo with alpha-[C11]methyl-L-tryptophan. Synapse 1998;28:33&ndash;43.
[PubMed]
https://doi.org/10.1002/(SICI)1098-2396(199801)28:1<33::AID-SYN5>3.0.CO;2-D
22.
Gill RC, Cote KR, Bowes KL, Kingma YJ: Human colonic smooth muscle: Spontaneous contractile activity and response to stretch. Gut 1986;27:1006&ndash;1013.
[PubMed]
23.
Fink S, Freedman G: The differential effects of drugs on the proximal and distal colon. Am J Med 1960;28:534&ndash;540.
24.
Lembo T, Naliboff B, Munakata J, Fullerton S, Saba L, Tung S, Schmulson M, Mayer EA: Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol 1999;94:1320&ndash;1326.
[PubMed]
25.
Schmulson M, Chang L, Naliboff B, Lee OY, Meyer EA: Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients. Am J Gastroenterol 2000;95:152&ndash;156.
[PubMed]
© 2001 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2001
You do not currently have access to this content.